The HDAC inhibitors panobinostat and vorinostat are epigenetic drugs that can be combined with other agents.
Panobinostat had a significant advantage when combined with bortezomib and dexamethasone over the same drugs with placebo; at the cost, however, of gastrointestinal symptoms and fatigue. Panobinostat combined with bortezomib and dexamethasone has been approved by the EMA for use in RRMM patients.
Footnotes
- Information on authorship, contributions, and financial & other disclosures was provided by the authors and is available with the online version of this article at www.haematologica.org.